Licensing out: try not to get benched
When licensing out a product to a bigger player, one of the risks is that the licensed product is shelved and the licensor never sees any revenue from it. As Colin McCall and Justyna Ostrowska explain, the licence agreement should anticipate that.
More 
SPC manufacturing waiver (Part 3): Notification obligations – Information is power
Verena Bertram and Anja Lunze examine the information obligations under the MW-Regulations.
More
COVID-19 and life sciences M&A
While the impact of COVID-19 is still being played out, our experts examine the already significant differences in how life sciences mergers and acquisitions are being carried out in this environment.
National perspectives on the CJEU Bayer decision
Our European team looks at what the CJEU decision in case C-688/17 may mean for national practice.
Taking security over IP: counting the cost
Martin Yells, Nina Goodyear and Josie Miller explain how in transactions where the IP is of significant value, careful consideration is required when creating security interests.
The 2020s: Boris Johnson's decade to prove his life sciences plan
Paul England discusses the potential impact of the Conservative Party election victory on the life sciences sector.
SPC manufacturing waiver (Part 1)
Verena Bertram and Anja Lunze address which activities the manufacturing waiver regulation actually privileges.
Arbitration: considerations for life science companies
In the second instalment of our Life Sciences Disputes series, our experts discuss the considerations for life sciences companies in arbitrations.
IP, divestments, fragmentation and the future: M&A in life sciences
Emma Danks discusses the latest M&A trends in life sciences.
Life Sciences Disputes webinar series
Tasmina Goraya and Paul England introduce our new webinar series focussed on life sciences disputes. More
∨ Archive
Answering one question and raising others – the CJEU on SPCs for new formulations
Bracing for Brexit if there is "no deal"
SPCs: where are we and where are we going? (an update)
Clinical trial liability – navigating the legal, regulatory and insurance landscape
Biosimilars – interchangeability/substitution and advertising
Ruling of the CJEU on Truvada SPC protection puts emphasis on skilled person's view
European Commission's 8th Report on the monitoring of patent settlements
CJEU rules on prescription support software as a medical device
Advocate General considers prescription support software to be a medical device
What is the significance of the Supreme Court decision on "pemetrexed disodium"? European Parliament adopts new Medical Device Regulations Notified Bodies potentially liable to end users of medical devices rules CJEU The Treatment - A guide for life sciences companies coming to Europe Medicines and medical devices regulation post-Brexit European Council approves Trade Secrets Directive Access to medicines in developing countries – what likely impact will GSK’s move have?
The challenge of true IP harmonisation
A changing industry and changing rights
Connected Health: regulatory issues
Hearing, seeing, moving - the miracle of neural prosthetics
Protection of technical trade secrets
Patent transactions in the life sciences
Asset-Centric special purpose vehicles (SPVs)
A consistently broad interpretation of health claim emerges in Europe
This month on Synapse
Read our monthly key lead articles in the Life Sciences.